Steroid therapy still plays a crucial role and could serve as a bridge to the next promising treatments in patients with IgG4‐related sclerosing cholangitis: Results of a Japanese nationwide study

Objective The acceptable duration of steroid therapy for patients with IgG4‐sclerosing cholangitis (SC) has been under debate. Our aim is to clarify the feasible duration of steroid treatment. Design We retrospectively reviewed the data of patients with IgG4‐SC and analyzed the following: biliary st...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hepato-biliary-pancreatic sciences 2022-08, Vol.29 (8), p.884-897
Hauptverfasser: Nakazawa, Takahiro, Takikawa, Hajime, Unno, Michiaki, Masamune, Atsushi, Okazaki, Kazuichi, Sawai, Shigeaki, Goto, Takuma, Otsuka, Masayuki, Tamano, Masaya, Koizumi, Mitsuhito, Hiasa, Yoichi, Kawabe, Naoto, Asano, Yukio, Watanabe, Hiroyuki, Toya, Daishu, Ohira, Hiromasa, Mukai, Tsuyoshi, Iwata, Keisuke, Shimizu, Shogo, Suetsugu, Jun, Tsuji, Keiji, Ishida, Ryoko, Ito, Masanori, Araki, Masahiro, Sakamoto, Yasunari, Takai, Satoshi, Ikeya, Shinichi, Yamada, Takanori, Ichiki, Yasunori, Kitada, Hideki, Hifumi, Michio, Kurosaki, Masayuki, Sumi, Hajime, Hayashi, Katsumi, Harada, Ryo, Nakamura, Shinichiro, Ito, Tetsuya, Oura, Kyoko, Masaki, Tsutomu, Shimokawahara, Naoto, Mizushima, Ichiro, Naganuma, Makoto, Murata, Miki, Nishio, Akiyoshi, Teratani, Takuma, Matsubara, Shohei, Azemoto, Ryousaku, Kamata, Ken, Kurosu, Takahiro, Fujita, Jun, Seki, Hideyuki, Ueda, Yasuhiro, Fukumoto, Takumi, Uchida, Kazushige, Ochiai, Toshimasa, Ishida, Etsuji, Mori, Hideaki, Sakagami, Junichi, Seno, Hiroshi, Naitoh, Itaru, Aoki, Toshinori, Mitoro, Akira, Yoshiji, Hitoshi, Yoshida, Motoyuki, Hayasaka, Kenji, Amano, Yuji, Terai, Shuji, Nakajima, Michiko, Yamahana, Junya, Iwatsu, Shinichi, Kato, Yuji, Horiguchi, Shigeru, Yagi, Takahito, Okada, Hiroyuki, Hirao, Motohiro, Imamura, Haruo, Shinobi, Tetsuya, Ryozawa, Shomei, Miyake, Tatsuya, Kohge, Naruaki, Tobita, Hiroshi, Joshita, Satoru, Kawaguchi, Shinya, Ohno, Kazuya, Yagi, Minami, Katanuma, Akio, Koike, Kazuhiko, Kagawa, Tatehiro, Azuma, Seishin, Kobayashi, Katsumasa, Asano, Toru, Taniguchi, Hideaki, Yasuda, Ichiro, Oe, Shinji, Harada, Masaru, Kurata, Masanao, Kawaji, Yuki, Kaino, Miyuki, Sakaida, Isao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective The acceptable duration of steroid therapy for patients with IgG4‐sclerosing cholangitis (SC) has been under debate. Our aim is to clarify the feasible duration of steroid treatment. Design We retrospectively reviewed the data of patients with IgG4‐SC and analyzed the following: biliary status during the steroid therapy, incidence of remission, relapse, relapse‐free survival rate, and steroid‐related complications (SRCs). Results Remission was achieved in 99.5% (763/767) of patients who received steroid therapy, while the remission rate dropped to 63.6% (78/129) of patients who did not receive it. Relapse was noted in 19.7% (151/763) of the patients who received steroid. Besides, relapse rate went up 38.4% (30/78) of the counterpart. Normalization of the serum total bilirubin and serum alkaline phosphatase levels were achieved at 2 weeks regardless of biliary drainage. Multivariate analysis identified younger onset, MST less than 3 years, immunosuppressant, and steroid cessation as independent risk factors for relapse. Steroid‐free was achieved in the patients underwent MST only 3.4% over 54 months. SRCs were recorded in a total of 99 patients (12.9%) despite sufficient preemptive medications. Multivariate analysis identified history of malignancy and immunosuppressant as independent risk factors for SRCs. Conclusion Steroid therapy should be continued for no
ISSN:1868-6974
1868-6982
DOI:10.1002/jhbp.1157